Cabozantinib (DrugBank: Cabozantinib)
1 disease| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 34 | 神経線維腫症 | 1 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02101736 (ClinicalTrials.gov) | June 2014 | 14/3/2014 | Cabozantinib for Plexiform Neurofibromas (PN) in Subjects With NF1 in Children and Adults | A Phase II Study of Cabozantinib (XL184) for Plexiform Neurofibromas in Subjects With Neurofibromatosis Type 1 in Children and Adults | NF1;Neurofibromatosis;Plexiform Neurofibromas | Drug: Cabozantinib | University of Alabama at Birmingham | NULL | Recruiting | 3 Years | N/A | All | 48 | Phase 2 | United States |